Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 18.28% since last year same period to $250.4Mn in the Q3 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated 3.49% jump in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 150.27% since last year same period to $32.77Mn in the Q3 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -1.87% fall in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin jumped 142.5% since last year same period to 13.09% in the Q3 2024. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -5.18% fall in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s price-to-earnings ratio after this Q3 2024 earnings stands at 21.45.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.05.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) jumped 150% since last year same period to 0.2 in the Q3 2024. This indicates that the Acadia Pharmaceuticals Inc. has generated 150% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acadia Pharmaceuticals Inc.’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acadia Pharmaceuticals Inc.’s return on equity (ROE) stands at 0.27.